REPL — Replimune Group, Inc.

REPLIMUNE Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2025, cash and cash equivalents totaled $483.8 million, up from $420.7 million year-over-year.
• Cash Runway: The company expects to fund operations into the fourth quarter of 2026, excluding potential revenue.
• Expenses:
  • R&D Expenses: $54 million for Q4 and $189.4 million for the fiscal year, up from $42.6 million and $175 million, respectively, year-over-year.
  • SG&A Expenses: $25.4 million for Q4 and $72.2 million for the fiscal year, compared to $16.2 million and $59.8 million in the prior year.
• Net Loss: Reported a net loss of $74.1 million for Q4 and $247.3 million for the fiscal year, compared to $55.1 million and $215.8 million in the previous year.

2. Strategic Updates and Business Highlights

• Product Development: Progress on the RP1 therapy, with a PDUFA date set for July 22, 2025, after being designated as a breakthrough therapy.
• Clinical Trials: The Ignite 3 confirmatory trial is underway, focusing on overall survival as the primary endpoint, with over 100 sites planned globally.
• Commercial Readiness: The company has built a customer-facing organization of approximately 60 people and established a distribution model for rapid delivery of RP1.
• Market Opportunity: RP1 is expected to target approximately 13,000 patients annually in the U.S. who progress after PD-1 treatment, with a focus on outpatient administration.

3. Forward Guidance and Outlook

• Investor Day: Scheduled for June 24, 2025, to discuss the melanoma landscape and the RP1 roadmap.
• Launch Expectations: Anticipated broad and rapid adoption of RP1 post-approval, with a focus on interventional radiologists and oncologists.
• Revenue Guidance: The company plans to provide metrics for tracking launch success but will hold off on formal revenue guidance until further into the launch.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The company reported a larger net loss compared to the previous year, raising concerns about financial sustainability until revenue generation begins.
• Regulatory Risks: Although the company is on track for the PDUFA date, any unforeseen issues during the FDA review process could impact timelines.
• Market Competition: The melanoma treatment landscape is evolving, and the company must ensure RP1 stands out against existing therapies.

5. Notable Q&A Insights

• Medical Education at ASCO: The company plans to present data supporting the efficacy of RP1 at the upcoming ASCO conference, focusing on the benefits of injecting superficial versus visceral lesions.
• Launch Trajectory: Expectations for rapid adoption are supported by positive feedback from over 90% of surveyed oncologists and interventional radiologists.
• Regulatory Interactions: The company has had consistent engagement with the FDA, with no identified impediments to the upcoming PDUFA date.
• Trial Enrollment: Focused efforts on enrolling U.S. sites for the Ignite 3 trial, with plans for continued enrollment globally post-approval.

This summary encapsulates the key points from Replimune's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, and future outlook while addressing potential challenges and insights from the Q&A session.